TEVA vs. TAK, ARGX, BNTX, ONC, INSM, SMMT, ITCI, GMAB, RDY, and MRNA
Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), BeOne Medicines (ONC), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Teva Pharmaceutical Industries vs. Its Competitors
Teva Pharmaceutical Industries (NYSE:TEVA) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.
In the previous week, Teva Pharmaceutical Industries and Teva Pharmaceutical Industries both had 5 articles in the media. Takeda Pharmaceutical's average media sentiment score of 1.27 beat Teva Pharmaceutical Industries' score of 0.65 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.
Takeda Pharmaceutical has a net margin of 2.36% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Takeda Pharmaceutical's return on equity.
Teva Pharmaceutical Industries has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.
Teva Pharmaceutical Industries presently has a consensus target price of $24.71, indicating a potential upside of 54.04%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.
54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 6.3%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.7%. Teva Pharmaceutical Industries pays out -87.9% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio.
Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 11 of the 18 factors compared between the two stocks.
Get Teva Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teva Pharmaceutical Industries Competitors List
Related Companies and Tools
This page (NYSE:TEVA) was last updated on 7/15/2025 by MarketBeat.com Staff
Free TEVA Stock Alerts